Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Table 6 Results of the univariate analysis of prognostic factors on overall survival, disease-free survival, local control

Factor	Overall Survival			Disease-free Survival			Local Control
Factor	HR	95%CI	P	HR	95%CI	P	HR	95%CI	P
Gender
male / female	0.849	0.334–2.160	0.731	1.280	0.674–2.434	0.451	0.588	0.125–2.771	0.502
Age
> 55 / <=55	0.737	0.325–1.672	0.465	0.872	0.476–1.599	0.658	2.002	0.518–7.742	0.315
Treatment
high-dose / low-dose	N/A	N/A	N/A	N/A	N/A	N/A	0.892	0.258–3.082	0.856
cT stage
cT4 / cT3	1.319	0.542–3.209	0.542	1.166	0.596–2.278	0.654	0.318	0.040–2.511	0.277
cN stage
cN+ / cN0	1.051	0.390–2.835	0.921	1.036	0.496–2.166	0.925	2.678	0.339–21.146	0.350
MRF
MRF+ / MRF-	2.971	1.297–6.802	0.010	2.485	1.351–4.572	0.003	4.802	1.240–18.590	0.023
Location
> 5 cm / ≤5 cm	1.191	0.515–2.753	0.683	0.888	0.462–1.709	0.723	0.484	0.103–2.280	0.359
Length
> 5 cm / ≤5 cm	1.563	0.662–3.693	0.308	1.219	0.658–2.260	0.528	2.059	0.532–7.965	0.296
ypT
ypT1–2/ypT0	1.047	0.294–3.734	0.944	1.672	0.641–4.363	0.294	1.797	0.187–17.278	0.612
ypT3–4 / ypT0	1.238	0.372–4.114	0.728	2.116	0.838–5.339	0.113	3.620	0.436–30.080	0.234
ypN
ypN+ / ypN0	3.518	1.346–9.191	0.010	2.234	1.178–4.234	0.014	0.776	0.201–3.004	0.714
pCR
non-pCR / pCR	2.728	0.639–11.646	0.175	2.656	0.946–7.459	0.064	2.058	0.261–16.257	0.494
Response
Poor / Good	2.574	1.013–6.544	0.047	2.228	1.156–4.297	0.017	1.224	0.345–4.339	0.755

Good response: pCR plus near pCR; Poor response: others
Abbreviations: HR Hazard ratio, pCR Pathological complete response, MRF Mesorectal fascia

ISSN: 1748-717X